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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
cannabis is effective in reducing muscle spasticity and body pain amongst patients with Multiple
Sclerosis (MS).
STUDY DESIGN: A systematic review of three peer-reviewed studies published between the
years of 2003 and 2012.
DATA SOURCES: Three randomized control trials (RCTs) evaluating if cannabis can reduce
muscle spasticity and body pain for patients diagnosed with Multiple Sclerosis. All three sources
were selected from PubMed and examined for outcomes that were patient oriented.
OUTCOMES MEASURED: The two primary outcomes measured include: muscle spasticity
measured by the Ashworth scale, and the patient’s perception of body pain measured by a
subjective Category Rating Scale (CRS).
RESULTS: The study conducted by Bloom et al.7 showed a significant reduction in muscle
spasticity by an average of 2.74 points more than the placebo group on the Ashworth scale.
Furthermore, the treatment reduced body pain by an average of 5.28 points more than the
placebo group when assessed on a Visual Analogue CRS. The MUSEC trial conducted by
Zajicek et al8 showed the relief from muscle stiffness after 12 weeks was almost twice as high
with cannabis extract than with placebo (29.4% vs 15.7%; OR 2.26; 95% CI 1.24 to 4.13;
p=0.004, one sided). Patient-reported body pain was also improved. The CAMS study conducted
by Zajieck et al9 found that treatment with cannabinoids did not have a beneficial effect on
spasticity when assessed with the Ashworth scale, but did find subjective improvement in
spasticity and pain via CRSs and asking patients direct questions about their overall opinion of
symptom improvement.
CONCLUSIONS: The result of three RCTs reveals conflicting evidence in regards to muscle
spasticity assessed by the Ashworth scale. However, clinically significant improvements of
patient-reported muscle spasticity and pain were recorded via use of CRSs in each trial. Due to
the limitations of these studies, further research is warranted.
KEY WORDS: Cannabis, Multiple Sclerosis, Pain, and Muscle Spasticity

INTRODUCTION
Multiple Sclerosis (MS) is an autoimmune, inflammatory demyelinating disease of the
Central Nervous System (CNS). The destruction of myelin impairs signal transmission within the
CNS and results in areas that develop scar tissue, resulting in a variety of symptoms. Some of the
most notable symptoms of this disease include: blurred vision, extreme fatigue, numbness, loss
of coordination, spasticity, and body pain. There are three distinct types of MS, however, the
most common type of MS follows a relapsing-remitting disease course. This is characterized by
clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial
or complete recovery.1 This paper evaluates three Randomized Control Trials (RCTs) that
analyze the efficacy of cannabis as treatment for improving muscle spasticity and body pain for
patients with MS.
MS currently affects more than 1 million individuals in the United States. and 2.3 million
globally. In the southern U.S., the prevalence rate is 57-78 cases per 100,000 versus 110-140
cases per 100,000 in the northern U.S.2 These statistics suggest that geographic location may be a
risk factor for the development of MS. Since healthcare providers are not required to report
patients diagnosed with MS, there is no definitive method to track how many patients have
developed this disease.
Healthcare costs are difficult to estimate and a are largely dependent upon the type and
severity of the patient’s symptoms. When specifically assessing the most common type of MS,
relapsing-remitting, it is estimated to cost a patient approximately $65,000 per year and $4.1
million dollars over the course of a lifetime. In addition, data shows that patient’s average 20
healthcare visits per year depending on the severity of their symptoms.3

The exact cause of MS is unknown, and it is unclear as to why it develops in some people
and not others. Although genetic and environmental factors are thought to play a role, the disease
is not contagious or inherited. The average age of onset is 20-50 years old and is at least two
times more common in women than men.4 MS initially manifests as a Clinically Isolated
Syndrome (CIS), which is an episode of neurologic symptoms caused by inflammation and
demyelination of nerve fibers in the CNS. Patients may present complaining of fatigue, gait
abnormalities, numbness/tingling, optic neuritis, pain, spasticity, and/or weakness. The diagnosis
of MS is initially made clinically with a history of at least two discrete episodes of symptomatic
exacerbations. Clinicians may confirm their suspicions of an MS diagnosis by ordering an MRI
with gadolinium, which will reveal white matter plaques in the brain. In addition, a diagnosis of
MS can also be supported via lumbar puncture to evaluate for the presence of oligoclonal bands
and increased IgG production. Once a diagnosis of MS is made a patient will be further
categorized as having 1 of 3 subtypes. These include: relapsing-remitting, primary progressive,
or secondary progressive. 1
Treatment for MS varies amongst patients. Typically, the first line medication for acute
exacerbations are high dose IV corticosteroids. If patients are not responsive to corticosteroids,
then plasmapheresis can be considered as a 2nd line treatment option.5 In regard to daily
maintenance therapy, the first line treatment is β-interferon. If this medication is not adequately
controlling the amount and severity of symptomatic relapses, then treatment with glatiramer
acetate is indicated. Adjunct medications include amantadine for fatigue and diazepam for
spasticity.6 Although these medications are useful in the treatment of MS, they are associated
with a heavy cost burden and the potential for adverse side effects.

OBJECTIVE
The objective of this selective EBM review is to determine whether or not cannabis is
effective in reducing muscle spasticity and body pain amongst patients with multiple sclerosis.

METHODS
The studies were evaluated and selected based on their adherence to specific criteria:
population studied, intervention used, comparison group, and outcomes measured. The studies
selected for this review needed to focus on patients 18 years or older that had a confirmed
diagnosis of MS. The intervention had to be cannabis, either smoked or oral administration.
Comparison groups using a placebo drug were preferentially selected for this review. The
outcomes measured needed to be patient-oriented evidence that matters (POEMs), which
included improvement in spasticity and body pain using both objective and subjective rating
scales. Each study used in this systematic review were RCTs comparing the effects of cannabis
to a controlled, placebo group. Two of the three studies were double-blind RCTs.
PubMed was used to find RCTs published in peer-reviewed journals in the English
language. They keywords “multiple sclerosis”, “cannabis”, “pain”, and “spasticity” were used
when searching for these articles. Selection of each article was based on relevance to the clinical
question, date of publication, generalizability, and outcomes that were patient oriented (POEMs).
Inclusion criteria for all three studies included articles that were peer-reviewed RCTs and
POEMs. Exclusion criteria were patients under the age of 18, disease-oriented evidence, and
preexisting Cochrane systematic reviews. The reported statistics included p-value, mean change
from baseline, and confidence intervals. Table 1 shows the demographics and characteristics of
included studies that were selected for this review.

Table 1 - Demographics & Characteristics of included studies
Study

Type

#
Pts
37

Age (yrs)

Inclusion Criteria

Exclusion Criteria

W/D

Intervention

Corey
Bloom7
(2012)

RCT

Avergae:
50 years
old

Patients who
were 18 years or
older with MS

Patients with a history of
major psychiatric disorder
(other than depression),
substance abuse,
neurologic disease (other
than MS), unstable
medical illness, pregnant
and breastfeeding women

7

Zajicek8 RCT
(2012)

279

18-64

Patients with
stable MS for the
past 6 months,
who have
ongoing muscle
stiffness for at
least 3 months
before
enrollment

Patients with active
sources of infection or
taking immunomodulatory
drugs that might affect
spasticity, fixed tendon
contractures, severe
cognitive impairment,
major illness, pregnancy,
cannabis use in the past 30
days, history of psychosis

53

Zajicek9 RCT
(2003)

667

18-64

Patients with
clinically definite
or laboratorysupported MS.
Disease must
have been stable
for the previous 6
months with
problematic
spasticity.

Ischemic heart disease,
56
patients > 64 years old,
active infection, severe
cognitive impairment ,
pregnancy, use of cannabis
in the 30 days prior to the
start of the study, past
history of psychotic
illness, patients taking
immunomodulator drugs
that may affect spasticity,
fixed tendon contractures

Smoked
cannabis
cigarettes (4%
delta-9-THC)
VS. Placebo
identical
cigarette. After
an 11-day
washout
interval,
participants
crossed over to
the opposite
group.
Oral cannabis
extract (titrated
over 2 weeks to
reach a
maximum dose
of 25mg daily)
VS. placebo.
Duration of
treatment was
12 weeks.
Patients were
assessed at
2,4,8, and 12
weeks
Oral Cannabis
extract & delta9-THC VS.
Placebo.
Duration of trial
was 15 weeks

OUTCOMES MEASURED
The outcomes measured were patient oriented (POEMs) and assessed by similar methods
across each study. Bloom et al.7 assessed muscle spasticity via the modified Ashworth rating
scale. Investigators combined ratings for both elbows, hips and knees for a total possible score of
30 points. Participants were assessed using this scale before and approximately 45 minutes after
treatment (cannabis or placebo) at each visit. In order to assess perceived pain, investigators
administered a subjective visual analogue scale to their participants.7
In the MUSEC trial, Zajiek et al.8 measured both muscle spasticity and body pain with
subjective category rating scales (CRS). Muscle spasticity was measured with an 11-point CRS
to evaluate perceived change in muscle stiffness after 12 weeks of treatment compared with the
premedication phase. At the final visit, participants answered the following question on a
symptom questionnaire: “Compared with before the study started, my muscle stiffness over the
last week has been…” providing a rating on an 11-point numerical CRS where 0 =
very much better, 5= no difference, and 10= very much worse. Ratings of 0-3 on the rating scale
were classified as a clinically relevant response.8 Body pain was also measured on a CRS at 4, 8,
and 12 weeks. Participants would answer the question, “Over the last week, the body pain I have
had is…” providing a rating in categories between “no body pain and “extreme body pain”.8
The CAMS study, also conducted by Zajiek et al.9 measured muscle spasticity with the
Ashworth rating scale. Assessments were made at six visits: two pre-treatment (visits 1 and 2),
three while on treatment (visits 5, 6, and 7), and one after discontinuation of treatment (visit 8).
At each visit, 10 muscle groups were evaluated on each side of the body while participants were
lying supine on a couch (or as close to this position as was tolerated) after resting for 15 minutes.
CRSs were also used in this study to subjectively measure muscle spasticity and pain. They were

administered at the end of the treatment phase only. Participants were asked to assess their
symptoms over the previous week and compare them with how they were just before the study
began. At the end of the 15 weeks, the treating doctor asked the participants specific questions
about the overall effect of the medication on spasticity and pain (visit 8). 9
RESULTS
This review consists of three RCTs that assessed whether cannabis is an effective
treatment for reducing muscle spasticity and body pain amongst patient with MS. Each trial
presented their outcomes as continuous data.
In the study conducted by Bloom et al.7, 196 patients were recruited for screening from a
regional MS clinic and by referral from specialists. Inclusion criteria included patients greater
than 18 years old and a baseline Ashworth score of at least 3 points. Patients were excluded if
they had a history of a major psychiatric disorder (other than depression), substance abuse,
neurologic disease (other than MS), pregnant or breastfeeding women, or an unstable medical
illness.7 Of the 196 patients recruited, 37 were randomized into either a smoked cannabis or
placebo group. Pre-rolled cannabis and placebo cigarettes were identical in appearance and
weight. Cannabis cigarettes contained 4% delta-9-tetrahydrocannabinol (delta-9-THC) by weight
while placebo cigarettes contained the same material with delta-9-THC removed.7 The Ashworth
scale was used to evaluate muscle spasticity and a visual analogue scale was administered to
evaluate body pain. By the end of the trial, 7 patients withdrew due to adverse side effects (n=4)
or unavailability for time commitment (n=3).7
Results show that smoking cannabis reduced Ashworth scale scores by an average of 2.95
points from baseline, which was 2.74 points more than placebo group (95% CI 2.20 to 3.14). Pvalue was calculated to be < 0.001. Smoking cannabis reduced patient scores on the visual

analogue scale by an average of 8.27 points from baseline, which was 5.28 points more than
placebo (95% CI 2.48 to 10.01). The calculated p-value for this scale was 0.008.7 Overall, this
trial showed a large and beneficial effect of smoked cannabis on spasticity and pain associated
with MS.
Although smoked cannabis was well-tolerated adverse effects were noted. These
included: dizziness, headache, fatigue, nausea, throat irritation, and feeling “too high”. As
mentioned previously, 4 patients withdrew from the trial due to intolerable side effects.
However, none of the participants experienced episodes of hypertension, hypotension,
tachycardia, or bradycardia that required medical intervention.
Table 2: Efficacy of smoked cannabis on muscle spasticity and body pain measured by the
Ashworth Scale and Visual Analogue Scale conducted by Bloom et al.7
Study: Bloom et. al 7
Mean Change from
CI (95%)
P-value
Baseline
Smoked cannabis:

-2.95

2.20 – 3.14

<0.001

-8.27

2.48 – 10.01

0.008

spasticity (Ashworth
Scale)
Smoked Cannabis:
body pain (Visual
Analogue Scale)

In 2012, Zajicek et al.8 conducted the MUSEC trial with a sample size of 279 patients.
Patients ranged from 18-64 years old and were required to have a diagnosis of MS according to
the McDonald Criteria. In addition, their disease had to have been stable for the previous 6
months with ongoing muscle stiffness for at least 3 months before the trial began.8 Exclusion

criteria included patients with active sources of infection or taking immunomodulatory drugs that
might affect spasticity, fixed tendon contractures, severe cognitive impairment, major illness,
pregnancy, cannabis use in the past 30 days, or history of psychosis.8
Patients were randomized to either an oral cannabis extract or placebo group via a
computer-generated voice response system. Both study groups received identical oral capsules
and all investigators and participants were blinded to treatment distribution throughout the trial.
The starting dose was 2.5mg of delta-9-tetrahydrocannabinol (Δ9THC) twice daily. Patients were
titrated up by 5mg every 3 days until a maximum dose of 25mg Δ9THC was achieved.8
Investigators administered CRSs to assess muscle spasticity and body pain. Results show
that the proportion of participants experiencing muscle relief after 12 weeks of oral cannabis was
nearly 2x higher than the placebo group (29.4% vs 15.7%; OR 2.26; 95% CI 1.24 to 4.13;
p=0.004, one sided). The mean reduction of muscle stiffness from baseline = -1.8 ±2.6.8 This
indicates a large treatment effect. Similar results were found when evaluating body pain. After
12 weeks, 28% of patients allocated to the cannabis extract group reported decreased body pain
as compared to 18.7% of patients in the placebo group (p=0.028). The mean reduction of body
pain from baseline = -1.2 ± 2.6 . This indicates a large treatment effect.8
Adverse events were most notable during the upward titration phase of Δ9THC. In the
cannabis extract group, 46.2% of patients experienced dizziness vs. only 6.7% in the placebo
group. In addition, 14% of cannabis patients reported feeling fatigued in comparison to only 6%
of placebo patients. Of the 279 patients randomized, 39 withdrew due to adverse events.8
Although side effects were noted, they were consistent with the known effects of cannabinoids.
No new safety concerns were detected, and the study achieved its goal to demonstrate the
usefulness of oral cannabis extract to treat muscle spasticity and body pain in patient with MS.

Table 3: Efficacy of oral cannabis extract on muscle spasticity and body pain measured by
Category Rating Scales conducted by Zajicek et al.8
Study: Zajieck et. al 8
Mean change from baseline
P-value
(Mean change ± SD)
Oral cannabis: spasticity

-1.8 ±2.6

0.004

Oral cannabis: body pain

-1.2 ± 2.6

0.028

The CAMS study conducted by Zajieck et al.9 enrolled 667 patients with MS. Of these
patients, 630 of them were randomized into one of the following groups: oral cannabis extract
(n=211), Δ9THC (n=206), or placebo (n=213). 9 Eligible patients were those between the age of
18-64 years old, clinically definite or laboratory-supported MS, and stable disease state for the
previous 6 months with problematic spasticity. Exclusion criteria included: ischemic heart
disease, active infection, severe cognitive impairment, pregnancy, use of cannabis in the 30 days
prior to the start of the study, history of psychotic illness, patients taking immunomodulator
drugs that may affect spasticity, and fixed tendon contractures. Throughout the duration of the
study 56 patients withdrew, leaving 611 to be assessed for efficacy and outcome measurements
over the next 10 weeks. 9
Compared to baseline assessments, results show a mean reduction in total Ashworth
score for patients taking oral cannabis extract vs. placebo to be 0.32 (95% CI -1.04 to 1.67;
p=0.40). For those patients taking Δ9THC vs. placebo the mean reduction in total Ashworth
score was 0.94 (95% CI -0.44 to 2.31). 9 The results of the Ashworth scale indicate that
cannabinoids did not have a clinically significant effect on reducing muscle spasticity. However,
there was evidence of treatment effect on patient-reported spasticity and pain measured by an 11point CRS. Improvement of spasticity was recorded in 61% of patients on cannabis extract

(n=121, 95% CI 54.6 – 68), 60% of patients receiving Δ9THC (n=108, 95% CI 52.5 – 66.8), and
46% of patients in the placebo group (n=91, 95% CI 39.0 - 52.90). In regard to body pain,
reductions were seen in 57%, 50%, and 37% of participants on cannabis extract, Δ9THC, and
placebo respectively. 9 Episodes of adverse events were most commonly seen in the active
treatment groups and were consistent with the known side effects of cannabinoids. These
included: dizziness, lightheadedness, increased appetite, dry mouth, urinary tract infection, and
diarrhea. 9
Table 4: Efficacy of oral cannabis extract and Δ9THC on muscle spasticity
measured by Ashworth scale conducted by Zajicek et al.9
Study: Zajieck et. al 9
Mean change from baseline
CI
Oral cannabis extract vs.

0.32

-1.04 to 1.67

0.94

-0.44 to 2.31

placebo- spasticity (Ashworth
scale)
Δ9THC vs. placebo- muscle
spasticity (Ashworth Scale)

DISCUSSION
Medical cannabis is legal in over 50% of the United States and is currently used by
patients who suffer from muscle spasms, severe pain, glaucoma, seizures, headaches, cancer,
HIV/AIDS, and Chron’s disease.10 Since cannabis is classified as a Schedule I substance, health
insurance companies will not help pay for the medication. Therefore, patients suffering from
debilitating diseases are forced to pay the full price.11 Research has resulted in the production of
three synthetic cannabinoid products: dronabinol, nabilone, and epidiolex. Epidiolex was
recently FDA-approved in June 2018 to treat Lennox-Gastaut syndrome and Dravet syndrome in
patients 2 years or older.10 Cannabis and synthetic cannabinoids are contraindicated in patients

with previous history of hypersensitivity reactions to medications, hepatic disease,
cardiovascular disease, women who are pregnant, history of substance abuse, and
coadministration with other CNS depressant medications.10
The three RCTs discussed in this review show statistical evidence that cannabinoids,
whether smoked or taken orally, are efficacious in reducing muscle spasticity and body pain for
patients with MS. Although one study did not show clinically significant improvement of
spasticity when assessed by the Ashworth scale9, subjective patient-oriented rating scales
consistently showed reductions in spasticity and body pain across all three studies. Future studies
would benefit by evaluating efficacy of this treatment method in elderly patients greater than 65
years old. Due to the newly approved FDA drug, Epidiolex, clinical trials assessing a pediatric
population is now warranted.
A notable limitation of each study discussed in this review is the ability to completely
blind participants from psychoactive substances. Participants could often tell which treatment
they were receiving. However, investigators noted that this limitation was unlikely to affect
objective spasticity scores. A second limitation is the reliability of the Ashworth scale. This
measurement tool was implemented for these clinical trials because it is the most widely used in
clinical practice. However, it is too insensitive to identify small but clinically significant effects
on spasticity. This may explain why the CAMS study failed to show clinically significant
improvement in muscle spasticity when assessed by the Ashworth scale.

CONCLUSION
The evidence presented in this review is conflicting as to whether or not cannabis is an
effective intervention for muscle spasticity and body pain. When measured via the Ashworth

scale, the study conducted by Bloom et al.7 showed a mean reduction of 2.95 points compared to
baseline scores. However, the CAMS study by Zajicek et al.9 did not show a clinically significant
effect with either oral cannabis extract or Δ9THC as they both reduced spasticity scores by less
than 1 point when compared to the placebo group. Data from the CRSs in each study consistently
proved that patient’s perceived the treatment to be effective in reducing muscle spasticity and
body pain.
When conducting future research on this topic, slower dose-titration of the oral cannabis
capsules need to be initiated. The MUSEC trial by Zajicek et al.8 titrated their oral cannabis
treatment over two weeks. Similarly, the methods of the CAMS study involved a short 5-week
titration period.9 This does not reflect normal clinical routine where dose titration can take a
more gradual course and side effects can be minimized. Future studies should also explore the
possibility of administering this treatment method via sublingual route. This would allow
investigators to more effectively achieve desired blood concentrations of the drug and increase
bioavailability, which may result in further reductions of muscle spasticity and body pain.
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